ULURU Inc. Announces the Completion of Production and Shipment of the Innovative 0.75 Gram Altrazeal® Blister Pack
Published: Oct 31, 2012
ADDISON, Texas, Oct. 31, 2012 /PRNewswire/ -- ULURU Inc. ("ULURU")(OTCQB: ULUR), announced today that the initial production of the Altrazeal® 0.75 gram blister pack has been completed and this product has been received in Australia.
The Altrazeal® 0.75 gram transparent blister pack incorporates an applicator within the blister design to assist the wound care professional to apply Altrazeal® to a wound. This highly innovative pack design has been extremely well accepted by the wound care community, in the U.S., Europe and Australia. Test marketing of this packaging concept was completed in the U.S. and Europe and produced extremely favourable endorsements from the participants in the study.
The blister pack configuration will be the only dosage form offered for sale in Europe. In addition to the innovative design, the 0.75 gram blister pack contains a more suitable amount of product to treat smaller chronic wounds. In the near future a 2 gram blister pack will be designed which will be introduced onto all international markets.
Commenting on the 0.75 gram blister pack production, Kerry P. Gray, President and CEO of ULURU, stated, "This product presentation reflects ULURU's commitment to address the market needs. The highly innovative blister design provides an applicator for the product and optimizes the application of Altrazeal® to the different wound types including diabetic foot ulcers and venous leg ulcers. This presentation further differentiates Altrazeal® in the advanced wound care market."
The shipment to Australia is very important as the introduction of the 0.75 gram blister pack will enable our partner to compete in all segments of the market. We anticipate that this product presentation will be the most commonly purchased unit.
Commenting on the Australia shipment, Helmut Kerschbaumer, Chairman of Melmed Holdings AG, added, "The initial response to Altrazeal® in Australia has been outstanding. The clinical and economic benefits of Altrazeal® have been demonstrated in the Australian clinics. I am extremely pleased with the properties of the transparent blister design including the "You See What You Get" concept and with the quality and innovative features of this product presentation as it reflects the high tech nature and major technical advancement that Altrazeal® provides the wound care market. This innovative packaging makes Altrazeal® even more distinctive in the international wound care market. The 0.75 gram blister pack now enables our partner to accelerate marketing activities as this is the product required by the wound care managers and hospital systems."
Further production is ongoing to supply the Austrian market and to enable the introduction of the 0.75 gram blister pack onto the U.S. Market. It is anticipated that further production will be necessary in 2012 to support the launch of Altrazeal® in additional international market.
Altrazeal® is a scientifically engineered advanced wound dressing designed to incorporate the desired features and benefits of the ideal wound dressings. Altrazeal® competes in the advanced wound dressing market which worldwide is estimated to be $6.5 billion growing annually at 13%. Altrazeal® has demonstrated potential clinical and economic advantages in a number of chronic and acute wounds including diabetic foot ulcers, venous ulcers, pressure ulcers and geriatric wounds.
About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through its innovative Nanoflex® Aggregate technology and OraDisc transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended. These statements are subject to numerous risks and uncertainties, including but not limited to our belief that Altrazeal® will be a dominant product in the advanced wound care market, the market acceptance of Altrazeal® in Europe and Australia, the innovative features and major technical advancement that Altrazeal® provides, the clinical and economic benefits of Altrazeal®, the favourable response to Altrazeal® in Australia, acceptance of the 0.75 gram blister pack, and to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2011, and other reports filed by us with the Securities and Exchange Commission.
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
SOURCE ULURU Inc.